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Ceftazidime pharmacokinetics in 28 preterm infants (gestational ages, 25.6 to 31.9 weeks) were studied on
day 3 of life. Patients with suspected septicemia were randomized on day 1 of life in two groups. One group
(n 5 13) was administered 25 mg of ceftazidime per kg of body weight once daily, and the other (n 5 15) was
given 25 mg of ceftazidime per kg twice daily. Both groups also received 25 mg of amoxicillin per kg twice daily.
Blood samples were collected on day 3 of life with an arterial catheter at 0, 0.5, 1, 2, 4, 8, and 12 h after an
intravenous bolus injection. An additional blood sample was taken at 24 h from the group dosed once a day.
High-performance liquid chromatography was used to determine serum ceftazidime concentrations. The
pharmacokinetics of ceftazidime were best described by using a one-compartment model. The half-life for the
elimination of the drug from serum, apparent volume of distribution, total body clearance of ceftazidime, and
inulin clearance were not significantly different for both groups. The ceftazidime/inulin clearance ratio was 0.72
for both groups. However, trough concentrations in serum for the twice-daily group were significantly (P <
0.001) higher (42.0 6 13.4 mg/liter) than those for the once-daily group (13.1 6 4.7 mg/liter). The latter
concentrations were all still substantially higher than the MIC of ceftazidime for major neonatal pathogens.
We conclude that the currently recommended dosage of 25 mg of ceftazidime per kg twice daily for preterm
infants with gestational ages below 32 weeks may be adjusted during the first days of life to one daily dose at
25 mg/kg, provided that for the empirical treatment of septicemia, amoxicillin at 25 mg/kg is also given twice
daily.
Ceftazidime, an expanded-spectrum cephalosporin, is com-
monly used in the treatment of bacterial infections in the
newborn (5). The currently recommended dosage regimen of
ceftazidime for preterm infants less than 4 weeks old and
whose birth weights are below 1,200 g is 25 to 100 mg/kg of
body weight given intravenously twice daily (18). However,
these dosage recommendations are based upon few pharma-
cokinetic data. Previous studies also did not stratify preterm
infants according to gestational age (GA) or postnatal age,
which has resulted in a substantial variability in pharmacoki-
netic parameters (3, 11–13, 17). We have previously demon-
strated that the pharmacokinetic behavior of ceftazidime in
preterm infants is strongly dependent on GA and postnatal
age. At a dosage of 25 mg of ceftazidime per kg given intra-
venously twice daily, high trough levels were observed, espe-
cially in infants with GAs below 32 weeks (21). High concen-
trations of beta-lactam antibiotics in serum and tissues do not
result in a more rapid killing of bacteria (4), but they may lead
to neutropenia and the impairment of cellular and humoral
immune responses (14). We therefore designed a prospective
randomized study to evaluate the pharmacokinetic effects of
reducing the dosage of ceftazidime from 25 mg/kg twice daily
to 25 mg/kg once daily for preterm infants with GAs below 32
weeks.
MATERIALS AND METHODS
Patients. Preterm infants (n5 28) admitted to the neonatal intensive care unit
of the Sophia Children’s Hospital between October 1991 and January 1992 with
suspected or documented septicemia were enrolled in this study. The inclusion
criteria were stability of hemodynamic function (a diuresis rate of .1 ml/kg/h
and systolic and diastolic blood pressure above the third percentile [adjusted for
GA]) and normal liver function. Infants receiving nephrotoxic or inotropic drugs
were excluded. All infants had an indwelling arterial catheter. The GAs of the
newborns were determined on the basis of the mother’s menstrual history and
were confirmed by early ultrasound examinations and by physical examination
based on the criteria of Dubowitz et al. (7). The study protocol was approved by
the Medical Ethical Committee of the University Hospital Rotterdam. Patients
were enrolled only after informed consent was obtained from the parents. Eli-
gible neonates were randomized at day 1 of life for 25 mg of ceftazidime per kg
given intravenously once or twice daily in combination with 25 mg of amoxicillin
per kg given intravenously twice daily. Patients with sterile cultures and without
a focus of infection received a total of 72 h of antibiotic therapy. Patients with
documented septicemia received at least 10 days of antibacterial treatment.
Pharmacokinetic study. The pharmacokinetics of ceftazidime were studied on
day 3 after birth. Blood samples were taken from the indwelling arterial lines
before the administration of an intravenous bolus injection of ceftazidime (time
zero) and at 0.5, 1, 2, 4, 8, and 12 h afterwards. An additional blood sample was
taken at 24 h for the once-daily group. Serum samples obtained after centrifu-
gation (Merck type Eppendorf 5414; 3,000 3 g for 1 min) were stored at 2708C.
Measurement of glomerular filtration rate. The glomerular filtration rate was
measured on day 3 after birth by means of the continuous inulin infusion tech-
nique (22, 23).
Ceftazidime assay. Analysis of serum ceftazidime concentrations was per-
formed by a modification of the high-performance liquid chromatography assay
described by Ayrton (1). Concentrations of ceftazidime in serum were calculated
from peak areas by comparison with those of standards in water containing 200,
100, 20, and 10 mg of ceftazidime per ml. Calibration curves were found to be
linear over the range of 10 to 200 mg of ceftazidime per ml. The lower limit of
detection of ceftazidime in serum was 0.5 mg/liter. The coefficients of interassay
variation at different concentrations were less than 7%. The intraassay values
were less than 5%. Recovery of 95% of the ceftazidime, which had been incu-
bated for 24 h at room temperature, was established.
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Pharmacokinetic analysis. Kinetic studies were performed on the third day of
life. Visual inspection of individual model fits gave no indication that a more
complex (e.g., two-compartment) pharmacokinetic model was required. Phar-
macokinetic parameters were calculated with the multiple-dose equation de-
scribed by Rowland and Tozer (19). The basic formula used was Ct 5 dose/V 3
(1 2 rN)/(1 2 r) 3 e2kt. In this formula, Ct is the concentration of ceftazidime
in plasma at a given time t, V is the apparent volume of distribution, N is the dose
number, and r is e2kt, in which k is the elimination rate constant and t is the
dosing interval. For the twice-daily group, the ceftazidime concentration-versus-
time curve was assumed to be attributable to the seventh dose (and the trough
level at time zero was assumed to be attributable to the sixth dose). For the
once-daily group, the ceftazidime concentration-versus-time curve was assumed
to be attributable to the third dose (and the trough level at time zero was
assumed to be attributable to the second dose). The data were weighted by
calculating 1/(predicted value)2. All calculations were carried out with the non-
linear regression module of SPSS/PC 1 V 4.0.1 (SPSS, Inc., Chicago, Ill.), which
uses a Levenberg-Marquardt algorithm.
Statistical analysis. Data given are means 6 standard deviations, unless indi-
cated otherwise. The comparison of mean values was done by the unpaired
Student t test. P values of #0.05 (two tailed) were considered significant.
RESULTS
Preterm infants (n 5 28) were enrolled in this study. After
randomization, 13 infants received 25 mg of ceftazidime per kg
once daily and 15 were treated with 25 mg of ceftazidime per
kg twice daily. All infants were also treated with 25 mg of
amoxicillin per kg twice daily. Both groups appeared to be well
matched on the basis of the demographic and clinical param-
eters of the patients (Table 1). All infants survived without any
short- or long-term sequelae. Data for the pharmacokinetic
parameters of ceftazidime and inulin clearance are given in
Table 2. No significant differences between the predose blood
sample and the poststudy dose trough concentration were
found for the once-daily (P 5 0.92) and twice-daily (P 5 0.89)
groups. Therefore, steady-state conditions were achieved. The
ceftazidime/inulin clearance ratio was 0.72 for both groups.
Glomerular filtration rates, as measured by inulin clearances,
were similar in both groups and were all within the same range
reported by us previously (21). Values for total body clearance,
apparent volume of distribution, serum elimination half-life,
and inulin clearance were not significantly different for both
groups. Serum trough levels for the twice-daily group (42.0 6
13.4 mg/liter) were significantly (P , 0.001) higher than those
for the once-daily group (13.1 6 4.7 mg/liter). The serum
ceftazidime concentrations over time for both groups are de-
picted in Fig. 1.
DISCUSSION
The clearance rates for many compounds, including antibi-
otics, are much lower for preterm infants than for term infants.
This can be attributed to the immaturity of renal function or
the hepatic drug metabolism (9, 16). Pharmacokinetic studies
are therefore necessary to optimize dosing regimens. We have
previously demonstrated that the use of the lowest recom-
mended dose for preterm infants, i.e., 25 mg of ceftazidime per
kg given intravenously twice daily, resulted in high concentra-
tions of ceftazidime in serum throughout the entire dosing
interval (21). However, serious side effects were not seen. Nev-
ertheless, high concentrations of ceftazidime may result in the
inhibition of cell proliferation in cultured human myeloid pre-
cursor and lymphoid cells (14). This might lead to neutropenia
and the impairment of cellular and humoral immune re-
sponses. In addition, a dose-dependent suppressive effect of
beta-lactam antibiotics on the differentiation and proliferation
of oligodendrocytes has been demonstrated in the rat model
(20). We questioned the validity of the current dosage recom-
mendations, and in a prospective, randomized way, we studied
the pharmacokinetic effects of a dosage reduction from 25 mg
of ceftazidime per kg twice daily to 25 mg/kg once daily for
preterm infants with GAs below 32 weeks.
The data presented in this paper indicate that twice-daily
dosing with ceftazidime leads to high serum trough concentra-
tions (42.0 6 13.4 mg/liter). Dosage reduction from twice daily
to once daily results in a significant (P , 0.001) reduction in
mean serum trough concentrations. However, the individual
values (8.1 to 25.6 mg/liter) are still well above the MIC of
ceftazidime for such major neonatal pathogens as Streptococ-
cus agalactiae and Escherichia coli (8, 15). The therapeutic
efficacy in animal models and for immunocompromised pa-
tients may be improved by the presence of concentrations of
beta-lactam antibiotics in serum which continuously exceed the
MIC (6, 25). This effect is achieved in adults by the continuous
infusion of ceftazidime or by intermittent administration of
high doses of ceftazidime two or three times daily. We show
here that ceftazidime has such a prolonged half-life in preterm
infants that once-daily administration of a low dose results in
concentrations (8.1 to 25.6 mg/liter) that are above the MICs
for major neonatal pathogens during the complete 24-h dosing
interval.
Our data also indicate that the mean ceftazidime/inulin
clearance ratios for both groups are similar (0.72). This is in
agreement with the results of previous studies showing ratios
of between 0.65 and 0.97 (2). The combination of a ceftazi-
dime/inulin clearance ratio of 0.72 and the previously reported
low (17%) protein binding suggests that renal elimination of
ceftazidime is almost completely mediated by glomerular fil-
tration (10). A recent study with adults indicated that in addi-
TABLE 1. Demographic and clinical parameters for the infants in the once- and twice-daily treatment groups
Group (no.) GA (wk)a Birth wt (g)a No. AGA/no. SGAb Artificial ventilation(no. with/no. without)
Treated once daily (13) 291⁄7 6 2.0 1,168 6 309 12/1 7/6
Treated twice daily (15) 294⁄7 6 2 1
7
1,141 6 400 12/3 8/7
a Values are means 6 standard deviations.
b AGA, appropriate size for GA; SGA, small for GA.
TABLE 2. Pharmacokinetic parameters of ceftazidime and inulin clearances of the infants in the once- and twice-daily treatment groupsa
Group (no.) CL (ml/h) CL (ml/h/kg) V (ml) V (ml/kg) t1/2 (h) CLin (ml/h) CLin (ml/h/kg)
Treated once daily (13) 32.46 10.9 27.8 6 5.8 376 6 120 323 6 62 8.15 6 1.18 45.0 6 7.2 38.6 6 3.8
Treated twice daily (15) 35.76 16.8 30.8 6 7.5 350 6 138 305 6 57 7.09 6 1.66 49.8 6 16.2 43.0 6 7.2
a CL, clearance; V, apparent volume of distribution; t1/2, elimination half-life; CLin, inulin clearance. Values are means 6 standard deviations.
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tion to glomerular filtration, some tubular excretion of cefta-
zidime, which is probably triggered by passive reabsorption,
occurs (24). At this moment, data on tubular excretion of
ceftazidime in the preterm infant are not available. In our
study, the coadministration of amoxicillin might have led to the
inhibition of tubular transport of ceftazidime by competition.
We conclude that the recommended twice-daily administra-
tion of ceftazidime in preterm infants with GAs below 32
weeks may be adjusted to once-daily dosing in the first days of
life. Alternatively, twice-daily dosing with doses lower than 25
mg/kg might even lead to an increased therapeutic effect com-
pared with that of once-daily dosing at 25 mg/kg (4, 14). How-
ever, for the empirical treatment of neonatal septicemia,
amoxicillin (at 25 mg/kg twice daily) should be added to the
antibiotic treatment protocol. These dosage recommendations
cannot yet be applied to infants with suspected or documented
meningitis, since data on the penetration of cerebrospinal fluid
in infants with once-daily dosing are missing.
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FIG. 1. Serum ceftazidime concentrations (means 6 standard deviations)
over time for once-daily (solid line) and twice-daily (dotted line) treatment
groups.
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